Ana María García Vicente1, Ángel Soriano Castrejón2, Jesús Fernando López-Fidalgo3, Mariano Amo-Salas3, María Del Mar Muñoz Sanchez4, Ruth Álvarez Cabellos5, Ruth Espinosa Aunión6. 1. Nuclear Medicine Department, University General Hospital, C/ Obispo Rafael Torija s/n., 13005, Ciudad Real, Spain. angarvice@yahoo.es. 2. Nuclear Medicine Department, University General Hospital, C/ Obispo Rafael Torija s/n., 13005, Ciudad Real, Spain. 3. Department of Mathematics, University of Castilla-La Mancha, Ciudad Real, Spain. 4. Oncology Department, Virgen de la Luz Hospital, Cuenca, Spain. 5. Oncology Department, Virgen de la Salud Hospital, Toledo, Spain. 6. Oncology Department, La Mancha Centro Hospital, Alcázar de San Juan, Ciudad Real, Spain.
Abstract
AIM: To explore the relationship between basal (18) F-FDG PET/CT information in breast tumours and survival in locally advanced breast cancer (LABC). METHODS: This prospective, multicentre study included 198 women diagnosed with LABC. All patients underwent (18) F-FDG PET/CT prior to treatment. The maximum standardized uptake value (SUVmax) in tumor (T), lymph nodes (N) and the N/T ratio was obtained in all cases. Stage according to PET/CT imaging (metabolic stage) and conventional imaging techniques (clinical stage) was established. During follow-up, patient status was established (disease free status or not). The relationship between all the variables and overall survival (OS) and disease-free survival (DFS) was analysed using the Kaplan-Meier and Cox regression methods. A ROC analysis was performed to obtain a cut-off value of SUVmax that was useful in the prediction of outcome. RESULTS: The mean SUVmax ± SD values in the primary tumour, lymph nodes and the SUVmax N/T index were 7.40 ± 5.57, 4.17 ± 4.74 and 0.73 ± 1.20, respectively. Higher semiquantitative metabolic values were found in more advanced metabolic and clinical stages. During follow-up, 78.4 % of patients were free of disease. Significant relationships were observed between SUVT and SUVN and patient status. With respect to OS and DFS, significant differences were detected for the metabolic stage. Kaplan-Meier analysis revealed that using the cut-off values, a primary-tumour SUVmax ≥ 6.05 or a nodal SUVmax ≥2.25 were significantly correlated with DFS and OS. CONCLUSION: PET imaging with (18) F-FDG offers prognostic information for LABC that can be obtained preoperatively and noninvasively.
AIM: To explore the relationship between basal (18) F-FDG PET/CT information in breast tumours and survival in locally advanced breast cancer (LABC). METHODS: This prospective, multicentre study included 198 women diagnosed with LABC. All patients underwent (18) F-FDG PET/CT prior to treatment. The maximum standardized uptake value (SUVmax) in tumor (T), lymph nodes (N) and the N/T ratio was obtained in all cases. Stage according to PET/CT imaging (metabolic stage) and conventional imaging techniques (clinical stage) was established. During follow-up, patient status was established (disease free status or not). The relationship between all the variables and overall survival (OS) and disease-free survival (DFS) was analysed using the Kaplan-Meier and Cox regression methods. A ROC analysis was performed to obtain a cut-off value of SUVmax that was useful in the prediction of outcome. RESULTS: The mean SUVmax ± SD values in the primary tumour, lymph nodes and the SUVmax N/T index were 7.40 ± 5.57, 4.17 ± 4.74 and 0.73 ± 1.20, respectively. Higher semiquantitative metabolic values were found in more advanced metabolic and clinical stages. During follow-up, 78.4 % of patients were free of disease. Significant relationships were observed between SUVT and SUVN and patient status. With respect to OS and DFS, significant differences were detected for the metabolic stage. Kaplan-Meier analysis revealed that using the cut-off values, a primary-tumour SUVmax ≥ 6.05 or a nodal SUVmax ≥2.25 were significantly correlated with DFS and OS. CONCLUSION: PET imaging with (18) F-FDG offers prognostic information for LABC that can be obtained preoperatively and noninvasively.
Authors: Christopher C Riedl; Elina Slobod; Maxine Jochelson; Monica Morrow; Debra A Goldman; Mithat Gonen; Wolfgang A Weber; Gary A Ulaner Journal: J Nucl Med Date: 2014-09-11 Impact factor: 10.057
Authors: Bong-Il Song; Chae Moon Hong; Hong Je Lee; Sungmin Kang; Shin Young Jeong; Hae Won Kim; Yee Soo Chae; Ji Young Park; Sang-Woo Lee; Byeong-Cheol Ahn; Jaetae Lee Journal: Nucl Med Mol Imaging Date: 2011-04-20
Authors: Onofrio Antonio Catalano; Gary Lloyd Horn; Alberto Signore; Carlo Iannace; Maria Lepore; Mark Vangel; Angelo Luongo; Marco Catalano; Constance Lehman; Marco Salvatore; Andrea Soricelli; Ciprian Catana; Umar Mahmood; Bruce Robert Rosen Journal: Br J Cancer Date: 2017-02-16 Impact factor: 7.640